A randomized trial of electronic clinical reminders to improve medication laboratory monitoring
- PMID: 18436905
- PMCID: PMC2442256
- DOI: 10.1197/jamia.M2602
A randomized trial of electronic clinical reminders to improve medication laboratory monitoring
Abstract
Objective: Recommendations for routine laboratory monitoring to reduce the risk of adverse medication events are not consistently followed. We evaluated the impact of electronic reminders delivered to primary care physicians on rates of appropriate routine medication laboratory monitoring.
Design: We enrolled 303 primary care physicians caring for 1,922 patients across 20 ambulatory clinics that had at least one overdue routine laboratory test for a given medication between January and June 2004. Clinics were randomized so that physicians received either usual care or electronic reminders at the time of office visits focused on potassium, creatinine, liver function, thyroid function, and therapeutic drug levels.
Measurements: Primary outcomes were the receipt of recommended laboratory monitoring within 14 days following an outpatient clinic visit. The effect of the intervention was assessed for each reminder after adjusting for clustering within clinics, as well as patient and provider characteristics.
Results: Medication-laboratory monitoring non-compliance ranged from 1.6% (potassium monitoring with potassium-supplement use) to 6.3% (liver function monitoring with HMG CoA Reductase Inhibitor use). Rates of appropriate laboratory monitoring following an outpatient visit ranged from 14% (therapeutic drug levels) to 64% (potassium monitoring with potassium-sparing diuretic use). Reminders for appropriate laboratory monitoring had no impact on rates of receiving appropriate testing for creatinine, potassium, liver function, renal function, or therapeutic drug level monitoring.
Conclusion: We identified high rates of appropriate laboratory monitoring, and electronic reminders did not significantly improve these monitoring rates. Future studies should focus on settings with lower baseline adherence rates and alternate drug-laboratory combinations.
Figures
References
-
- Beach JE, Faich GA, Bormel FG, Sasinowski FJ. Black box warnings in prescription drug labeling: results of a survey of 206 drugs Food & Drug Law Journal 1998;53(3):403-411. - PubMed
-
- Schoenenberger RA, Tanasijevic MJ, Jha A, Bates DW. Appropriateness of antiepileptic drug level monitoring[see comment] JAMA 1995;274(20):1622-1626Nov 22–29. - PubMed
-
- Graham DJ, Drinkard CR, Shatin D, Tsong Y, Burgess MJ. Liver enzyme monitoring in patients treated with troglitazone JAMA 2001;286(7):831-833Aug 15. - PubMed
-
- Calabrese AT, Coley KC, DaPos SV, Swanson D, Rao RH. Evaluation of prescribing practices: risk of lactic acidosis with metformin therapy Arch Intern Med 2002;162(4):434-437Feb 25. - PubMed
-
- Roblin DW, Nielsen DM. Assessment of quality in adult primary care: developing process measures from administrative data Clin Perform Qual Health Care 1994;2:200-208.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
